[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469696":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":28,"responsibleParty":44,"collaborators":7,"id":47,"slug":7,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","phlebotomy","500ml of blood phlebotomized per standard of care to reduce symptoms from polycythemia",[14],{"name":15,"affiliation":16,"role":17},"Jaap Jan Zwaginga, MD, PhD","LUMC","PRINCIPAL_INVESTIGATOR",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":23},"Rik Tonino, MD","CONTACT","+31623248432","r.p.b.tonino@lumc.nl",{"name":15,"role":21,"phone":25,"phoneExt":26,"email":27},"071 526 9111","+31","j.j.zwaginga@lumc.nl",[29],{"facility":16,"status":30,"city":31,"state":32,"zip":7,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Leiden","South Holland","Netherlands",{"type":35,"coordinates":36},"Point",[37,38],4.49306,52.15833,{"lat":38,"lon":37},[41,42],{"name":20,"role":21,"phone":7,"phoneExt":7,"email":23},{"name":15,"role":21,"phone":7,"phoneExt":7,"email":43},"J.J.zwaginga@lumc.nl",{"type":17,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"jjzwaginga","Prof. dr. J.J. Zwaginga","100469696",false,"NCT05396170","Effect of Phlebotomy on Heartrate in Polycythemia Patients","Phlebotomy in Blood Donors and Polycythemia Vera Patients- The Effect on Physiology: An Orienting Case-Cross Over Study","NOSFERATU","Inclusion Criteria:\n\n* Patients with polycythaemia, requiring phlebotomy on a regular basis (at least every 4 months)\n* Subjects aged ≥18 years\n* In possession of a smartphone\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Poor performance\u002Ffunctional status (Eastern Cooperative Oncology Group system ECOG ≥3)\n* Participants with known arrhythmias or other significant cardiological conductivity disorders (Paroxysmal atrial fibrillation is allowed)\n* Hospitalized subjects\n* Subjects with a pacemaker.\n* Subjects with a secondary polyglobulia due to eg smoking or other pulmonary issues.\n* Scheduled oncological treatments or surgery during the study period.","ALL","18 Years",{"count":57,"type":58},10,"ESTIMATED","OBSERVATIONAL","Single-centre, observational within-subject design: patients that undergo phlebotomies regularly for polycythemia will be measured continuously by wearables one week before until one week after a phlebotomy, for three phlebotomies.",[62],"Polycythemia","2024-11-12",{"date":65,"type":66},"2024-11-13","ACTUAL",{"date":68,"type":66},"2022-07-21",{"date":70,"type":58},"2025-01-01",{"name":5,"class":6},1]